Stay updated on Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial

Sign up to get notified when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy evaluation using objective response rate (ORR) for patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma in a phase II trial involving autologous tumor infiltrating lymphocytes MDA-TIL.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:37.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit specific descriptions based on factors like general health or prior treatments. The new text also provides an example of inclusion criteria, such as the requirement for subjects to provide informed consent and meet certain health conditions.
    Difference
    48%
    Check dated 2024-05-22T21:11:05.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:21:50.000Z thumbnail image

Stay in the know with updates to Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Autologous TIL MDA-TIL in Recurrent Cancer Clinical Trial page.